Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muFAP-CD40
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**muFAP-CD40** is a bispecific antibody designed to activate the **CD40** receptor conditionally in the presence of **fibroblast activation protein α (FAP)**, a protease specifically expressed in the stroma of solid tumors. By targeting both FAP and CD40, the agonist restricts CD40 activation to the tumor microenvironment, thereby overcoming toxicity and "sink" effects typical of nontargeted CD40 agonists. This targeting enables higher and more effective dosing, resulting in potent T-cell priming, intratumoral immune activation, and tumor regression, while minimizing systemic adverse effects. This approach is under preclinical and early clinical development as an innovative cancer immunotherapy[1][2][3][4].
- Other names
- FAP-CD40FAP-CD-40FAP-CD 40
02
Targets
CD40 (Cluster of differentiation 40 receptor)FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on muFAP-CD40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muFAP-CD40.